Doheny Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Doheny Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-10,400	Closed	-$345K	–	114
2017 Q2	$345K	Sell	10,400 -1,400	-12%	-$43.3K	0.16%	85
2017 Q1	$379K	Sell	11,800 -300	-2%	-$10.2K	0.17%	83
2016 Q4	$439K	Sell	12,100 -500	-4%	-$20K	0.21%	74
2016 Q3	$580K	Hold	12,600	–	–	0.3%	69
2016 Q2	$633K	Sell	12,600 -250	-2%	-$13.3K	0.32%	65
2016 Q1	$688K	Hold	12,850	–	–	0.35%	64
2015 Q4	$843K	Sell	12,850 -25	-0.2%	-$1.54K	0.41%	61
2015 Q3	$727K	Sell	12,875 -25	-0.2%	-$1.62K	0.38%	61
2015 Q2	$762K	Hold	12,900	–	–	0.34%	66
2015 Q1	$804K	Hold	12,900	–	–	0.37%	63
2014 Q4	$742K	Hold	12,900	–	–	0.35%	65
2014 Q3	$693K	Sell	12,900 -1,715	-12%	-$90.9K	0.35%	67
2014 Q2	$766K	Sell	14,615 -100	-0.7%	-$5.11K	0.36%	61
2014 Q1	$778K	Sell	14,715 -1,000	-6%	-$46.2K	0.4%	60
2013 Q4	$630K	Hold	15,715	–	–	0.33%	66
2013 Q3	$594K	Sell	15,715 -25,180	-62%	-$982K	0.33%	66
2013 Q2	$1.6M	Buy	+40,895	New	+$1.59M	0.92%	43

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Doheny Asset Management's TEVA Position: Q3 2017 in Review

Doheny Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 10,400 shares — an estimated $345K sold.

Doheny Asset Management first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $1.6M in Q2 2013. 536 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Doheny Asset Management reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Doheny Asset Management sold 10,400 Teva Pharmaceuticals shares in Q3 2017, an estimated $345K.
Doheny Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 17 quarters.
Doheny Asset Management's Teva Pharmaceuticals position peaked at $1.6M in Q2 2013.
536 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Doheny Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.